FFM
NBIX icon

Forum Financial Management’s Neurocrine Biosciences NBIX Stock Holding History

Forum Financial Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,467
Closed -$350K – 748
2025
Q4 		$350K Buy
2,467
+14
+0.6% +$2.03K ﹤0.01% 665
2025
Q3 		$344K Buy
2,453
+560
+30% +$75.9K ﹤0.01% 662
2025
Q2 		$238K Buy
1,893
+36
+2% +$4.13K ﹤0.01% 800
2025
Q1 		$205K Sell
1,857
-2
-0.1% -$253 ﹤0.01% 806
2024
Q4 		$254K Buy
+1,859
New +$230K ﹤0.01% 719

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Forum Financial Management's NBIX Position: Q1 2026 in Review

Forum Financial Management sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 2,467 shares — an estimated $350K sold.

Forum Financial Management first reported a position in NBIX in Q4 2024 and held it in 5 quarters. The position peaked at $350K in Q4 2025. 700 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Forum Financial Management reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Forum Financial Management sold 2,467 Neurocrine Biosciences shares in Q1 2026, an estimated $350K.
  • Forum Financial Management first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 5 quarters.
  • Forum Financial Management's Neurocrine Biosciences position peaked at $350K in Q4 2025.
  • 700 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Forum Financial Management's 13F filing for Q1 2026, filed 23 Apr 2026.